Our pharmacokinetic analysis of the antiretroviral TAF has been published in Clinical Infectious Diseases (CID)!

📢 We are thrilled to announce the publication of our latest paper in Clinical Infectious Diseases (CID). Our paper reports the first pharmacokinetic data of TAF and TFV in children taking dolutegravir or boosted protease inhibitors. 

🔬 Findings:

We observed that when tenofovir alafenamide fumarate (TAF) was administered according to the WHO-recommended weight bands and combined with either dolutegravir or ritonavir-boosted protease inhibitors, the children showed adequate exposure to both TAF and tenofovir. 

🌍 Impacting on Pediatric HIV Care:  

These data contribute to the practical use of TAF within regimens available in sub-Saharan Africa and other low- and middle-income settings. 

🙏 This achievement would not have been possible without the collaborative efforts of our esteemed team of researchers (CHAPAS-4 website), clinicians, and the invaluable support from the participating children and their families. We extend our deepest gratitude to everyone involved in making this study a success, including EDCTP for funding this trial.